You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Histone deacetylase inhibitor. Causes cell differentiation and antiproliferative activity in MCF-7 human breast cancer cells in vitro and displays antitumor activity in vivo. Also exhibits antiproliferative, proapoptotic and differentiation effects in pediatric acute myeloid leukemia cell lines.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 174.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.74 mL||28.71 mL||57.42 mL|
|5 mM||1.15 mL||5.74 mL||11.48 mL|
|10 mM||0.57 mL||2.87 mL||5.74 mL|
|50 mM||0.11 mL||0.57 mL||1.15 mL|
References are publications that support the biological activity of the product.
Martirosyan et al (2004) Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model. Biochem.Pharmacol. 68 1729 PMID: 15450938
Martirosyan et al (2006) Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J.Pharmacol.Exp.Ther. 317 546 PMID: 16497787
Wiggers et al (2019) Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. Pediatr.Blood Cancer. PMID: 31044544
If you know of a relevant reference for NSC 3852, please let us know.
View Related Products by Product Action
Keywords: NSC 3852, NSC 3852 supplier, Histone, deacetylases, inhibitors, inhibits, HDAC, NSC3852, epigenetics, Non-selective, HDACs, Non-Selective, 2521, Tocris Bioscience
Citations for NSC 3852
Citations are publications that use Tocris products.
Currently there are no citations for NSC 3852. Do you know of a great paper that uses NSC 3852 from Tocris? Please let us know.
Reviews for NSC 3852
There are currently no reviews for this product. Be the first to review NSC 3852 and earn rewards!
Have you used NSC 3852?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.